SecBot SecBot
SECBOTREPLAY Home › Report › MNKD

MNKD · MannKind reported strong fourth quarter and full year 2025 financial…

MANNKIND CORP · 8-K filed Feb 26, 2026 at 08:03 ET

At the news

BULLISHIMPACT 8/10

8-K filed Feb 26, 2026 at 08:03 ET

MannKind reported strong fourth quarter and full year 2025 financial results, with Q4 revenue up 46% year-over-year to $112 million and full year revenue up 22% to $349 million, driven by the acquisition of scPharma and growth in Afrezza and Furoscix sales. The company also highlighted upcoming FDA catalysts for Afrezza in pediatrics and Furoscix ReadyFlow Autoinjector.

  • Q4 2025 revenue was $111.96 million, a 46% increase from $76.78 million in Q4 2024
  • Full year 2025 revenue was $348.97 million, up 22% from $285.50 million in 2024
  • Furoscix generated $23.18 million in net sales following the October 2025 acquisition of scPharma
  • Afrezza Q4 2025 net sales were $22.88 million, up 25% from Q4 2024

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access